Efficacy of a medical food on cognition in Alzheimer's Disease: Results from secondary analyses of a randomized, controlled trial

Journal of Nutrition, Health and Aging

Volumn 15, Issue 8, 2011, Pages 720-724

  Kamphuis, P J G H ^a,b   Verhey, F R J ^c   Olde Rikkert, M G M ^d   Twisk, J W R ^e   Swinkels, S H N ^a   Scheltens, Philip ^f  

^a DANONE RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; cognition; nutrition; treatment outcome

Indexed keywords

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOOD; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOUVENAID; TREATMENT OUTCOME;

EID: 84856294228     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-011-0105-6     Document Type: Article

References (30)

1. Rosenstein LD (1998) Differential diagnosis of the major progressive dementias and depression in middle and late adulthood a summary of the literature of the early 1990s. Neuropsychol Rev 8 (3): 109-167. (Pubitemid 28554535)
2. Selkoe DJ(2002) Alzheimer's disease is asynaptic failure. Science 298:789-791.
3. Terry RD (2006) Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol 19 (3): 125-128. (Pubitemid 44154851)
4. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, and Marzloff G (2006) Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 1088(1):83-92. (Pubitemid 43729416)
5. Cansev M and Wurtman RJ (2007) Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience 148(2): 421-431. (Pubitemid 47364815)
6. Cansev M, Wurtman RJ, Sakamoto T, and Ulus IH (2008) Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimeis Dement 4(1 Suppl 1):S153-S168.
7. Sakamoto T, Cansev M, and Wurtman RJ (2007) Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 1182:50-59. (Pubitemid 350086992)
8. Arellano JI, Espinosa A, Fairen A, Yuste R, and DeFelipe J (2007) Non-synaptic dendritic spines in neocortex. Neuroscience 145(2):464-469. (Pubitemid 46341650)
9. Toni N, Teng EM, Bushong EA, Aimone JB, Zhao C, Consiglio A, van Praag H, Marione ME, Ellisman MH, and Gage EH (2007) Synapse formation on neurons bom in the adult hippocampus. NatNeurosci 10 (6):727-34. (Pubitemid 46828514)
10. Hering H and Sheng M (2001) Dendritic spines: structure, dynamics and regulation. Nat Rev Neurosci 2 (12):880-888. (Pubitemid 33674075)
11. US Department of Health and Human Services FaDA, Center for Food Safety and Applied Nutrition, Frequently Asked Questions About Medical Foods. 2007.
12. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, and Kurz A (2010) Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement 6 (1):1-10el.
13. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, and Thai LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11Suppl 2:S13-S21.
14. Wechsler D (1987) Wechsler Memory Scale - Revised Manual. San Diego: Psychological corp.
15. Littell RC, Milliken GA, Stroup WW, and Wolfinger RD (1996) SAS? System for Mixed Models. Cary, NC: SAS Institute, Inc. 633.
16. Fitzmaurice G, Laird N, and Ware J (2004) Applied longitudinal analysis. Hoboken, New Jersey: John Wiley & Sons.
17. Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, and Stern Y (2009) Scales as outcome measures for Alzheimer's disease. Alzheimers Dement 5(4):324-39.
18. Vellas B, Andrieu S, Sampaio C, and Wilcock G (2007) Disease-modifying trials in Alzheimer's disease: A European task force consensus. Lancet Neurol 6(1):56-62. (Pubitemid 44880273)
19. Benge JF, Balsis S, Geraci L, Massman PJ, and Doody RS (2009) How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Dement GeriatrCogn Disord 28(1):63-69.
20. Ferris SH, Lucca U, Mohs R, Dubois B, Wesnes K, Erzigkeit H, Geldmacher D, and Bodick N (1997) Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 11 Suppl3:34-38. (Pubitemid 127726418)
21. Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, Albert K, and Schindler R (2009) Rates of cognitive change in Alzheimer disease: Observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis Assoc Disord 23(4):357-364.
22. Schneider LS and Sano M (2009) Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 5(5):388-397.
23. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, and Davis KL (1994) A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151(3):390-396. (Pubitemid 24081459)
24. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, and Tensfeldt T Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6(1):39-53.
25. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, and Richardson S (2004) Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 61(12): 1852-1856. (Pubitemid 39612945)
26. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, and Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama 302(23):2557-2564.
27. Van Gool WA, Weinstein HC, Scheltens P, and Walstra GJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358(9280):455-460. (Pubitemid 32769852)
28. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Moller HJ, Kurz A, and Basun H (2009) Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70(6):922-931.
29. Vellas B, Andrieu S, Sampaio C, Coley N, and Wilcock G (2008) Endpoints fortrials in Alzheimer's disease: a Europe an task force consensus. Lancet Neurol 7(5):436-450. (Pubitemid 351509424)
30. Sampaio C (2007) Clinical relevance on Alzheimer's disease endpoints. J Nutr Health Aging 11(4):316-317. (Pubitemid 47121929)